Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win

Outlook Therapeutics has notched a win in its uphill battle to commercialize an ophthalmic version of Roche’s Avastin (bevacizumab) in the U.S., with the FDA now agreeing that the drug has demonstr | After a formal dispute resolution process that followed three prior rejections, the FDA has decided that Outlook's eye drug candidate Lytenava has shown evidence of effectiveness.